Stock LXEO LEXEO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Lexeo Therapeutics, Inc. Stock

Equities

LXEO

US52886X1072

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
12.5 USD +2.80% Intraday chart for Lexeo Therapeutics, Inc. +3.73% -6.86%
Apr. 22 Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug MT
Apr. 16 Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy MT

Financials (USD)

Sales 2024 * - Sales 2025 * 900K Capitalization 412M
Net income 2024 * -78M Net income 2025 * -84M EV / Sales 2024 * -
Net cash position 2024 * 225M Net cash position 2025 * 120M EV / Sales 2025 * 324 x
P/E ratio 2024 *
-3.99 x
P/E ratio 2025 *
-4.11 x
Employees 58
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.4%
More Fundamentals * Assessed data

Chart Lexeo Therapeutics, Inc.

Dynamic Chart

Latest news about Lexeo Therapeutics, Inc.

Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug MT
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy MT
Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy DJ
Lexeo Therapeutics, Inc. Announces the U.S. Food and Drug Administration Grants Fast Track Designation for LX2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich?s Ataxia Cardiomyopathy CI
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Global BMI Index CI
Lexeo Therapeutics Raises $95 Million Via Private Placement of Shares MT
Lexeo Therapeutics, Inc. announced that it has received $94.999833 million in funding from a group of investors CI
RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept MT
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell MT
LEXEO: ENTERED INTO COMMON STOCK PURCHASE AGREEMENT TO… RE
Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding CI
Lexeo Therapeutics Promotes Sandi See Tai to Chief Development Officer, Makes Other Appointments MT
Lexeo Therapeutics, Inc. Strengthens Clinical Development Leadership with New Executive Appointments CI
Lexeo Soars After Gene Therapy for Cardiac Disorder Receives Orphan Drug, Fast Track Designations MT
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P TMI Index CI
More news

Analyst Recommendations on Lexeo Therapeutics, Inc.

RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept MT
Chardan Initiates Lexeo Therapeutics With Buy Rating, $23 Price Target MT
Stifel Starts Lexeo Therapeutics With Buy Rating, $20 Price Target MT
RBC Initiates Lexeo Therapeutics at Outperform, Speculative Risk With $22 Price Target Amid 'Undemanding' Valuation, Upcoming Catalysts MT
JPMorgan Starts Lexeo Therapeutics With Overweight Rating, $20 Price Target MT
More recommendations

Press releases Lexeo Therapeutics, Inc.

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy AQ
LEXEO THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR LX2006, AN AAV-BASED GENE THERAPY CANDIDATE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA CARDIOMYOPATHY AQ
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy AQ
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing AQ
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights AQ
More press releases

Quotes and Performance

1 day+2.80%
1 week+3.73%
Current month-20.28%
1 month-18.14%
3 months-24.29%
Current year-6.86%
More quotes

Highs and lows

1 week
11.76
Extreme 11.76
13.10
1 month
11.57
Extreme 11.57
16.02
Current year
11.57
Extreme 11.57
22.33
1 year
9.00
Extreme 9
22.33
3 years
9.00
Extreme 9
22.33
5 years
9.00
Extreme 9
22.33
10 years
9.00
Extreme 9
22.33
More quotes

Quotes

Date Price Change Volume
24-04-26 12.5 +2.80% 377,218
24-04-25 12.16 -2.72% 51,316
24-04-24 12.5 +2.97% 99,355
24-04-23 12.14 -4.11% 82,174
24-04-22 12.66 +5.06% 229,958

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes

Company Profile

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Sector
Biotechnology & Medical Research
Calendar
2024-05-13 - RBC Capital Markets Global Healthcare Conference
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.5 USD
Average target price
21.4 USD
Spread / Average Target
+71.20%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LEXEO THERAPEUTICS, INC. Stock Lexeo Therapeutics, Inc.
-6.86% 412M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LXEO Stock